# EAA241 (NCT07085728)

> Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07085728
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Eastern Cooperative Oncology Group
- Conditions: Myeloma Multiple
- Interventions: Cyclophosphamide; Bortezomib (VELCADE); Dexamethasone; Daratumumab-hyaluronidase
- Enrollment: 74
- Primary outcome: Renal Response Rate

## Indexed commentary on EAA241 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 50
- Bluesky threads: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=eaa241-nct07085728

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07085728", "email": "<work email>"}; the inbox owner confirms by the emailed link.